Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

Colorectal tumors that underwent somatic next-generation sequencing (NGS) for 154-168 genes in an in-house laboratory between 2015 and 2022 were retrospectively identified. Microsatellite instability ...

Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways ...

Druggable phosphatases in cancer and immune cells, with examples of their corresponding drugs. Structures of allosteric inhibitors targeting PP2A, PRL3, DUSP1/6, and SHP2 in cancer cells (left).

Natural products have historically served as a vital source of chemotherapeutic agents, laying the foundation for many standard-of-care drugs. However, the ...

QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

A newly identified interaction between ovarian cancer cells and surrounding abdominal cells helps explain the cancer’s ...